Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.

Sinnaeve PR, Schwartz GG, Wojdyla DM, Alings M, Bhatt DL, Bittner VA, Chiang CE, Correa Flores RM, Diaz R, Dorobantu M, Goodman SG, Jukema JW, Kim YU, Pordy R, Roe MT, Sy RG, Szarek M, White HD, Zeiher AM, Steg PG; ODYSSEY OUTCOMES Investigators.

Eur Heart J. 2019 Nov 16. pii: ehz809. doi: 10.1093/eurheartj/ehz809. [Epub ahead of print]

PMID:
31732742
2.

Initiating PCSK9 Inhibition in Hospital for ACS: We Can, But Does That Mean We Should?

Schwartz GG, Chaitman BR.

J Am Coll Cardiol. 2019 Nov 19;74(20):2463-2465. doi: 10.1016/j.jacc.2019.09.039. No abstract available.

PMID:
31727283
3.

Patients with High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit from Alirocumab Treatment in the Odyssey Outcomes Trial.

Damask A, Steg PG, Schwartz GG, Szarek M, Hagström E, Badimon L, Chapman MJ, Boileau C, Tsimikas S, Ginsberg HN, Banerjee P, Manvelian G, Pordy R, Hess S, Overton JD, Lotta LA, Yancopoulos GD, Abecasis GR, Baras A, Paulding C; Regeneron Genetics Center and the ODYSSEY OUTCOMES Investigators.

Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044434. [Epub ahead of print]

PMID:
31707832
4.

Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial.

Szarek M, Steg PG, DiCenso D, Bhatt DL, Bittner VA, Budaj A, Diaz R, Goodman SG, Gotcheva N, Jukema JW, Pordy R, Roe MT, Sourdille T, White HD, Xavier D, Zeiher AM, Schwartz GG.

Circ Cardiovasc Qual Outcomes. 2019 Nov;12(11):e005858. doi: 10.1161/CIRCOUTCOMES.119.005858. Epub 2019 Nov 11.

PMID:
31707826
5.

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES.

Jukema JW, Zijlstra LE, Bhatt DL, Bittner VA, Diaz R, Drexel H, Goodman SG, Kim YU, Pordy R, Reiner Z, Roe MT, Tse HF, Valdovinos PCM, White HD, Zeiher AM, Szarek M, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Investigators.

Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.043826. [Epub ahead of print] No abstract available.

PMID:
31707788
6.

Thyroid Cancer Incidence Rates in North Dakota are Associated with Land and Water Use.

Schwartz GG, Klug MG.

Int J Environ Res Public Health. 2019 Oct 10;16(20). pii: E3805. doi: 10.3390/ijerph16203805.

7.

Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease.

Haarhaus M, Ray KK, Nicholls SJ, Schwartz GG, Kulikowski E, Johansson JO, Sweeney M, Halliday C, Lebioda K, Wong N, Brandenburg V, Beddhu S, Tonelli M, Zoccali C, Kalantar-Zadeh K.

Atherosclerosis. 2019 Nov;290:59-65. doi: 10.1016/j.atherosclerosis.2019.09.002. Epub 2019 Sep 17.

8.

Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.

Ray KK, Nicholls SJ, Ginsberg HD, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Cummings JL, Sweeney M, Schwartz GG.

Am Heart J. 2019 Aug 9;217:72-83. doi: 10.1016/j.ahj.2019.08.001. [Epub ahead of print]

PMID:
31520897
9.

Serum 25-hydroxyvitamin D levels predict cancer survival: a prospective cohort with measurements prior to and at the time of cancer diagnosis.

Robsahm TE, Tretli S, Torjesen PA, Babigumira R, Schwartz GG.

Clin Epidemiol. 2019 Aug 8;11:695-705. doi: 10.2147/CLEP.S207230. eCollection 2019.

10.

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.

Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-Jaramillo P, Lopes RD, Louie MJ, Moriarty PM, Szarek M, Vogel R, White HD, Zeiher AM, Baccara-Dinet MT, Steg PG, Schwartz GG.

Circulation. 2019 Nov 5;140(19):1578-1589. doi: 10.1161/CIRCULATIONAHA.119.042551. Epub 2019 Sep 2.

PMID:
31475572
11.

Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.

Koomen JV, Heerspink HJL, Schrieks IC, Schwartz GG, Lincoff AM, Nicholls SJ, Svensson A, Wedel H, Weichert A, Grobbee DE, Stevens J.

Diabetes Obes Metab. 2019 Aug 29. doi: 10.1111/dom.13862. [Epub ahead of print]

PMID:
31468659
12.

Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery.

Goodman SG, Aylward PE, Szarek M, Chumburidze V, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Hanotin C, Harrington RA, Jukema JW, Kedev S, Letierce A, Moryusef A, Pordy R, Ramos López GA, Roe MT, Viigimaa M, White HD, Zeiher AM, Steg PG, Schwartz GG; ODYSSEY OUTCOMES Committees and Investigators.

J Am Coll Cardiol. 2019 Sep 3;74(9):1177-1186. doi: 10.1016/j.jacc.2019.07.015.

PMID:
31466614
13.

An exploration of colorectal cancer incidence rates in North Dakota, USA, via structural equation modeling.

Schwartz GG, Klug MG, Rundquist BC.

Int J Colorectal Dis. 2019 Sep;34(9):1571-1576. doi: 10.1007/s00384-019-03352-9. Epub 2019 Jul 16.

PMID:
31312891
14.

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.

Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators.

Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Erratum in: Lancet Diabetes Endocrinol. 2019 Jul 8;:. Lancet Diabetes Endocrinol. 2019 Sep;7(9):e21.

PMID:
31272931
15.

PCSK9 Function and Cardiovascular Death: The Knot Tightens.

Schwartz GG, Taylor MRG.

J Am Coll Cardiol. 2019 Jun 25;73(24):3115-3117. doi: 10.1016/j.jacc.2019.03.518. No abstract available.

PMID:
31221260
16.

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.

White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lopes RD, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Sritara P, Tricoci P, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators.

Eur Heart J. 2019 Sep 1;40(33):2801-2809. doi: 10.1093/eurheartj/ehz299.

17.

Effect of Alirocumab on Mortality After Acute Coronary Syndromes.

Steg PG, Szarek M, Bhatt DL, Bittner VA, Brégeault MF, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Ostadal P, Parkhomenko A, Pordy R, Roe MT, Tricoci P, Vogel R, White HD, Zeiher AM, Schwartz GG.

Circulation. 2019 Jul 9;140(2):103-112. doi: 10.1161/CIRCULATIONAHA.118.038840. Epub 2019 May 23. Erratum in: Circulation. 2019 Jul 23;140(4):e171.

18.

Alirocumab after Acute Coronary Syndrome. Reply.

Schwartz GG, Steg PG, Szarek M.

N Engl J Med. 2019 May 23;380(21):2077. doi: 10.1056/NEJMc1902955. No abstract available.

PMID:
31116934
19.

Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial.

Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Karpov Y, Moryusef A, Pordy R, Prieto JC, Roe MT, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators.

J Am Coll Cardiol. 2019 Sep 3;74(9):1167-1176. doi: 10.1016/j.jacc.2019.03.013. Epub 2019 Mar 18.

20.

Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.

Mani P, Puri R, Schwartz GG, Nissen SE, Shao M, Kastelein JJP, Menon V, Lincoff AM, Nicholls SJ.

JAMA Cardiol. 2019 Apr 1;4(4):314-320. doi: 10.1001/jamacardio.2019.0179.

PMID:
30840024
21.

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.

Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Kimura T, Kiss RG, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Tricoci P, Xavier D, Zeiher AM, Steg PG; ODYSSEY OUTCOMES Committees and Investigators.

J Am Coll Cardiol. 2019 Feb 5;73(4):387-396. doi: 10.1016/j.jacc.2018.10.039. Epub 2018 Nov 11.

22.

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators.

N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.

PMID:
30403574
23.

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.

Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S.

Lancet. 2018 Oct 13;392(10155):1311-1320. doi: 10.1016/S0140-6736(18)31652-0. Epub 2018 Oct 4.

PMID:
30293769
24.

Preoperative Use of Statins in Carotid Artery Stenting: A Systematic Review and Meta-analysis.

Texakalidis P, Giannopoulos S, Jonnalagadda AK, Chitale RV, Jabbour P, Armstrong EJ, Schwartz GG, Kokkinidis DG.

J Endovasc Ther. 2018 Oct;25(5):624-631. doi: 10.1177/1526602818794030. Epub 2018 Aug 13.

PMID:
30101624
25.

Ovarian Cancer Incidence in the U.S. and Toxic Emissions from Pulp and Paper Plants: A Geospatial Analysis.

Hanchette C, Zhang CH, Schwartz GG.

Int J Environ Res Public Health. 2018 Jul 31;15(8). pii: E1619. doi: 10.3390/ijerph15081619.

26.

Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial.

Nicholls SJ, Andrews J, Kastelein JJP, Merkely B, Nissen SE, Ray KK, Schwartz GG, Worthley SG, Keyserling C, Dasseux JL, Griffith L, Kim SW, Janssan A, Di Giovanni G, Pisaniello AD, Scherer DJ, Psaltis PJ, Butters J.

JAMA Cardiol. 2018 Sep 1;3(9):815-822. doi: 10.1001/jamacardio.2018.2121.

27.

Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone.

Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz ES, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN; IRIS Investigators.

Circulation. 2018 Sep 18;138(12):1210-1220. doi: 10.1161/CIRCULATIONAHA.118.034763.

28.

Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.

Schrieks IC, Nozza A, Stähli BE, Buse JB, Henry RR, Malmberg K, Neal B, Nicholls SJ, Rydén L, Mellbin L, Svensson A, Wedel H, Weichert A, Lincoff AM, Tardif JC, Grobbee DE, Schwartz GG.

Diabetes Care. 2018 Aug;41(8):1792-1800. doi: 10.2337/dc18-0158. Epub 2018 Jun 14.

29.

Radon and lung cancer: What does the public really know?

Vogeltanz-Holm N, Schwartz GG.

J Environ Radioact. 2018 Dec;192:26-31. doi: 10.1016/j.jenvrad.2018.05.017. Epub 2018 Jun 5. Review.

30.

Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.

Stähli BE, Nozza A, Schrieks IC, Buse JB, Malmberg K, Mellbin L, Neal B, Nicholls SJ, Rydén L, Svensson A, Wedel H, Weichert A, Lincoff AM, Grobbee DE, Tardif JC, Schwartz GG.

J Clin Endocrinol Metab. 2018 Jul 1;103(7):2522-2533. doi: 10.1210/jc.2017-02772.

31.

Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial.

Schwartz GG, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Nicholls SJ, Olsson AG, Shah PK, Tardif JC, Kittelson J.

JAMA Cardiol. 2018 Feb 1;3(2):164-168. doi: 10.1001/jamacardio.2017.3833.

32.

Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes.

Savonitto S, Morici N, Nozza A, Cosentino F, Perrone Filardi P, Murena E, Morocutti G, Ferri M, Cavallini C, Eijkemans MJ, Stähli BE, Schrieks IC, Toyama T, Lambers Heerspink HJ, Malmberg K, Schwartz GG, Lincoff AM, Ryden L, Tardif JC, Grobbee DE.

Diab Vasc Dis Res. 2018 Jan;15(1):14-23. doi: 10.1177/1479164117735493. Epub 2017 Oct 20.

PMID:
29052439
33.

Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease.

Nicholls SJ, Ray KK, Johansson JO, Gordon A, Sweeney M, Halliday C, Kulikowski E, Wong N, Kim SW, Schwartz GG.

Am J Cardiovasc Drugs. 2018 Apr;18(2):109-115. doi: 10.1007/s40256-017-0250-3.

PMID:
29027131
34.

Enuresis and Constipation in a 12-Year-Old.

Schwartz GG, Hillman PR, Omoruyi EV, Mazur LJ.

Clin Pediatr (Phila). 2018 Jan;57(1):121-124. doi: 10.1177/0009922816688738. Epub 2017 Feb 13. No abstract available.

PMID:
28952347
35.

County level incidence rates of chronic lymphocytic leukemia are associated with residential radon levels.

Oancea SC, Rundquist BC, Simon I, Swartz S, Zheng Y, Zhou X, Sens MA, Schwartz GG.

Future Oncol. 2017 Sep;13(21):1873-1881. doi: 10.2217/fon-2017-0165. Epub 2017 Aug 24.

36.

Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.

Povsic TJ, Scott R, Mahaffey KW, Blaustein R, Edelberg JM, Lefkowitz MP, Solomon SD, Fox JC, Healy KE, Khakoo AY, Losordo DW, Malik FI, Monia BP, Montgomery RL, Riesmeyer J, Schwartz GG, Zelenkofske SL, Wu JC, Wasserman SM, Roe MT.

Cardiovasc Drugs Ther. 2017 Aug;31(4):445-458. doi: 10.1007/s10557-017-6739-9. Review.

PMID:
28735360
37.

Prediagnostic serum calcium and albumin and ovarian cancer: A nested case-control study in the Norwegian Janus Serum Bank Cohort.

Schwartz GG, Tretli S, Vos L, Robsahm TE.

Cancer Epidemiol. 2017 Aug;49:225-230. doi: 10.1016/j.canep.2017.07.004. Epub 2017 Jul 18.

38.

Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome.

Schwartz GG, Fayyad R, Szarek M, DeMicco D, Olsson AG.

Eur J Prev Cardiol. 2017 Aug;24(12):1294-1296. doi: 10.1177/2047487317708677. Epub 2017 May 15. Review.

PMID:
28504565
39.

Metformin prevents ischaemic ventricular fibrillation in metabolically normal pigs.

Lu L, Ye S, Scalzo RL, Reusch JEB, Greyson CR, Schwartz GG.

Diabetologia. 2017 Aug;60(8):1550-1558. doi: 10.1007/s00125-017-4287-2. Epub 2017 May 11.

40.

Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome.

Morici N, Savonitto S, Ponticelli C, Schrieks IC, Nozza A, Cosentino F, Stähli BE, Perrone Filardi P, Schwartz GG, Mellbin L, Lincoff AM, Tardif JC, Grobbee DE.

Am J Med. 2017 Sep;130(9):1068-1075. doi: 10.1016/j.amjmed.2017.02.033. Epub 2017 Mar 24.

PMID:
28344139
41.

Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692.

Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN; IRIS Trial Investigators.

Diabetes Care. 2017 Apr;40(4):e47-e48. doi: 10.2337/dci16-0048. No abstract available.

42.

Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus.

Young LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, Furie KL, Gorman MJ, Conwit R, Abbott JD, Jacoby DL, Kolansky DM, Pfau SE, Ling FS, Kernan WN; IRIS Investigators.

Circulation. 2017 May 16;135(20):1882-1893. doi: 10.1161/CIRCULATIONAHA.116.024863. Epub 2017 Feb 28.

43.

Who Should Receive Ezetimibe?

Schwartz GG.

J Am Coll Cardiol. 2017 Feb 28;69(8):922-923. doi: 10.1016/j.jacc.2016.12.013. No abstract available.

44.

Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.

Andrews J, Janssan A, Nguyen T, Pisaniello AD, Scherer DJ, Kastelein JJ, Merkely B, Nissen SE, Ray K, Schwartz GG, Worthley SG, Keyserling C, Dasseux JL, Butters J, Girardi J, Miller R, Nicholls SJ.

Cardiovasc Diagn Ther. 2017 Feb;7(1):45-51. doi: 10.21037/cdt.2017.01.01.

45.

Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure.

Pitts R, Gunzburger E, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, Nicholls SJ, Shah PK, Tardif JC, Olsson AG, McMurray JJ, Kittelson J, Schwartz GG.

J Am Heart Assoc. 2017 Jan 10;6(1). pii: e004119. doi: 10.1161/JAHA.116.004119.

46.

Geographic distributions of motor neuron disease mortality and well water use in U.S. counties.

Schwartz GG, Rundquist BC, Simon IJ, Swartz SE.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):279-283. doi: 10.1080/21678421.2016.1264975. Epub 2016 Dec 25.

PMID:
28019106
47.

Association of Perioperative Statin Use With Mortality and Morbidity After Major Noncardiac Surgery.

London MJ, Schwartz GG, Hur K, Henderson WG.

JAMA Intern Med. 2017 Feb 1;177(2):231-242. doi: 10.1001/jamainternmed.2016.8005.

PMID:
27992624
48.

Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein.

Pitts R, Gunzburger E, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Nicholls SJ, Niesor EJ, Olsson AG, Shah PK, Tardif JC, Kittelson J, Schwartz GG.

J Am Coll Cardiol. 2016 Dec 6;68(22):2488-2490. doi: 10.1016/j.jacc.2016.09.932. No abstract available.

49.

Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.

Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN; IRIS Trial Investigators.

Diabetes Care. 2016 Oct;39(10):1684-92. doi: 10.2337/dc16-0798. Epub 2016 Jul 27.

50.

Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes.

Tardif JC, Rhainds D, Brodeur M, Feroz Zada Y, Fouodjio R, Provost S, Boulé M, Alem S, Grégoire JC, L'Allier PL, Ibrahim R, Guertin MC, Mongrain I, Olsson AG, Schwartz GG, Rhéaume E, Dubé MP.

Circ Cardiovasc Genet. 2016 Aug;9(4):340-8. doi: 10.1161/CIRCGENETICS.116.001405. Epub 2016 Jul 14.

Supplemental Content

Loading ...
Support Center